Betsy Bryant
University of North Carolina at Chapel Hill
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Betsy Bryant.
The Diabetes Educator | 2004
Russell L. Rothman; Robb Malone; Betsy Bryant; Cheryl Horlen; Darren A. DeWalt; Michael Pignone
PURPOSE This study examined the role of literacy in patients with poorly controlled diabetes who were participating in a diabetes management program that included low-literacy-oriented interventions. METHODS A before-after analysis was performed of a pharmacist-led diabetes management program for 159 patients with type 2 diabetes and poor glycemic control (hemoglobin A1c [A1C] > or = 8.0%). Clinic-based pharmacists offered one-to-one education and medication management for these patients using techniques that did not require high literacy. Literacy was measured by the Rapid Estimate of Adult Literacy in Medicine (REALM) test and dichotomized at the 6th-grade level. The A1C values were collected prior to enrollment, at enrollment, and approximately 6 months after enrollment. RESULTS Of the 111 patients with follow-up data, 55% had literacy levels at the 6th-grade level or below. Lower literacy was more common among African Americans, older patients, and patients who required medication assistance. There was no significant relationship between literacy status and A1C prior to enrollment or at enrollment. Over the 6-month study period, patients with low and high literacy had similar improvements in A1C. CONCLUSIONS This diabetes care program, which used individualized teaching with low-literacy techniques, significantly improved A1C values independent of literacy status.
The Diabetes Educator | 2005
Russell L. Rothman; Robb Malone; Betsy Bryant; Catherine Wolfe; Penelope J. Padgett; Darren A. DeWalt; Morris Weinberger; Michael Pignone
Purpose The purpose of this study was to develop and validate a new knowledge scale for patients with type 2 diabetes and poor literacy: the Spoken Knowledge in Low Literacy patients with Diabetes (SKILLD). Methods The authors evaluated the 10-item SKILLD among 217 patients with type 2 diabetes and poor glycemic control at an academic general medicine clinic. Internal reliability was measured using the Kuder-Richardson coefficient. Performance on the SKILLD was compared to patient socioeconomic status, literacy level, duration of diabetes, and glycated hemoglobin (A1C). Results Respondents’ mean age was 55 years, and they had diabetes for an average of 8.4 years; 38% had less than a sixth-grade literacy level. The average score on the SKILLD was 49%. Less than one third of patients knew the signs of hypoglycemia or the normal fasting blood glucose range. The internal reliability of the SKILLD was good (0.72). Higher performance on the SKILLD was significantly correlated with higher income (r= 0.22), education level (r= 0.36), literacy status (r= 0.33), duration of diabetes (r= 0.30), and lower A1C (r= –0.16). When dichotomized, patients with low SKILLD scores (= 50%) had significantly higher A1C (11.2% vs 10.3%, P< .01). This difference remained significant when adjusted for covariates. Conclusion The SKILLD demonstrated good internal consistency and validity. It revealed significant knowledge deficits and was associated with glycemic control. The SKILLD represents a practical scale for patients with diabetes and low literacy.
Journal of Medical Genetics | 2006
Tao Li; Leslie A. Lange; Xiangli Li; Lisa Susswein; Betsy Bryant; Robb Malone; Ethan M. Lange; Teng-Ti Huang; Darrel Stafford; James P. Evans
Background: Warfarin is a mainstay of therapy for conditions associated with an increased risk of thromboembolic events. However, the use of this common agent is fraught with complications and little is known regarding inter-individual variation in warfarin response. Objective: We tested for association between single nucleotide polymorphisms (SNPs) in VKORC1 and CYP2C9 and average weekly warfarin dose required to maintain patients at their desired anticoagulation target. Methods: The sample consisted of 93 European-American patients from anticoagulation clinics at the University of North Carolina at Chapel Hill. Data on mean weekly warfarin dose were collected over a mean treatment period of 20.6 months. ANCOVA models were used and haplotype analysis was performed. Results: Three of six VKORC1 SNPs were found to be very strongly associated with the average warfarin dose required to achieve the target international normalised ratio (INR; p<0.0001). The mean weekly dose by genotype ranged from approximately 27 to 47 mg. There was no evidence for an association between either of the two CYP2C9 polymorphisms studied, CYP2C9*2 and CYP2C9*3. CYP2C9*3 was significantly (p = 0.05) associated with average warfarin dosage after adjustment for VKORC1*1173. Conclusions: These results are of considerable clinical interest and confirm recently published results regarding the role of these two genes in modifying warfarin metabolism and maintenance dosage. The consistent findings regarding the role of VKORC1 and CYP2C9 in warfarin metabolism and maintenance dosage represent a clinically useful proof of principal for the use of pharmacogenomic information in medicine and may lead to improved understanding of warfarin’s actions.
American Journal of Medical Quality | 2003
Russell L. Rothman; Robb Malone; Betsy Bryant; Cheryl Horlen; Michael Pignone
We developed and evaluated a comprehensive pharmacist-led, primary care-based diabetes disease management program for patients with Type 2 diabetes and poor glucose control at our academic general internal medicine practice. The primary goal of this program was to improve glucose control, as measured by hemoglobin A1c (HbA1c). Clinic-based pharmacists offered support to patients with diabetes through direct teaching about diabetes, frequent phone follow-up, medication algorithms, and use of a database that tracked patient outcomes and actively identified opportunities to improve care. From September 1999, to May 2000, 159 subjects were enrolled, and complete follow-up data were available for 138 (87%) patients. Baseline HbA1c averaged 10.8%, and after an average of 6 months of intervention, the mean reduction in HbA1c was 1.9 percentage points (95% confidence interval, 1.5-2.3). In predictive regression modeling, baseline HbA1c and new onset diabetes were associated with significant improvements in HbA1c. Age, race, gender, educational level, and provider status were not significant predictors of improvement. In conclusion, a pharmacist-based diabetes care program integrated into primary care practice significantly reduced HbA1c among patients with diabetes and poor glucose control.
JAMA | 2004
Russell L. Rothman; Darren A. DeWalt; Robb Malone; Betsy Bryant; Ayumi Shintani; Britton Crigler; Morris Weinberger; Michael Pignone
The American Journal of Medicine | 2005
Russell L. Rothman; Robb Malone; Betsy Bryant; Ayumi Shintani; Britton Crigler; Darren A. DeWalt; Robert S. Dittus; Morris Weinberger; Michael Pignone
Patient Education and Counseling | 2004
Darren A. DeWalt; Michael Pignone; Robb Malone; Cathy Rawls; Margaret C. Kosnar; Geeta George; Betsy Bryant; Russell L. Rothman; Bonnie F Angel
JAMA | 2002
Cheryl Horlen; Robb Malone; Betsy Bryant; Betty Dennis; Tim Carey; Mike Pignone; Russell L. Rothman
The American Journal of Managed Care | 2006
Russell L. Rothman; Stephanie A. So; John H. Shin; Robert M. Malone; Betsy Bryant; Darren A. DeWalt; Michael Pignone; Robert S. Dittus
JAMA | 2002
Mark E. Molitch; William E. Cayley; Russell L. Rothman; Michael Pignone; Betsy Bryant; Robb Malone; Cheryl Horlen